Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMN4CV5)

Drug Name
Calcidiol Drug Info
Synonyms
Calcifediolum; Calcifidiol; Delakmin; VDY; Calcifediol anhydrous; BML2-E02; Calcifediolum [INN-Latin]; Ro 8-8892; U-32070E; (1R,3Z)-3-[(2E)-2-[(1R,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol; (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol; (3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; (3S,5Z,7E)-9,10-secocholesta-5,7,10-triene-3,25-diol; (3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; (5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; (5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-3beta,25-diol; 25(OH)D3; 25-(OH)Vitamin D3; 25-Hydroxycholecalciferol; 25-Hydroxycholecalciferol (Calcifediol); 25-Hydroxycholescalciferol; 25-Hydroxyvitamin D; 25-Hydroxyvitamin D3 monohydrate; 25-hydroxyvitamin D3; 3-{2-[1-(5-HYDROXY-1,5-DIMETHYL-HEXYL)-7A-METHYL-OCTAHYDRO-INDEN-4-YLIDENE]-ETHYLIDENE}-4-METHYLENE-CYCLOHEXANOL; 5,6-cis-25-Hydroxyvitamin D3; 5,6-trans-25-Hydroxycholescalciferol; 5,6-trans-9,10-Seco-5,7,10(19)-cholestatrien-3beta,25-diol; 9,10-Secocholesta-5,7,10(19)-triene-3beta,25-diol
Indication
Disease Entry ICD 11 Status REF
Hypophosphatemia Approved [1]
Renal osteodystrophy Approved [2]
Rickets 5B57 Approved [3]
Vitamin D deficiency 5B57 Approved [4]
Autosomal dominant hypocalcemia 5A50.0Y Investigative [5]
Therapeutic Class
Vitamins
Cross-matching ID
PubChem CID
5283731
ChEBI ID
CHEMBL1040
CAS Number
CAS 19356-17-3
TTD Drug ID
DMN4CV5
INTEDE Drug ID
DR0259
ACDINA Drug ID
D00089

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Vitamin D3 receptor (VDR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ergocalciferol DMHO0AR Hypoparathyroidism 5A50 Approved [6]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [11]
Doxercalciferol DM6FG1P Chronic kidney disease GB61 Approved [12]
Calcipotriol DM03CP7 Psoriasis EA90 Approved [13]
Falecalcitrol DMBI9ZJ Hyperparathyroidism 5A51 Approved [14]
Dihydrotachysterol DMFB97P Hypocalcemia 5B5K.1 Approved [15]
Cholecalciferol DMGU74E Adult acute monocytic leukemia Approved [16]
Paricalcitol DMYBV3G Hyperparathyroidism 5A51 Approved [17]
Seocalcitol DMKL9QO Rickets 5B57 Phase 3 [18]
S-06911 DMAYTIH Osteoporosis FB83.0 Phase 3 [19]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Vitamin D(3) 24-hydroxylase (CYP24A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [20]
Drug(s) Affected By 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (CYP24A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [21]
Calcipotriol DM03CP7 Psoriasis EA90 Approved [22]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [23]
Quercetin DM3NC4M Obesity 5B81 Approved [24]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [25]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [26]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [27]
Liothyronine DM6IR3P Congenital hypothyroidism Approved [28]
Testosterone DM7HUNW Hot flushes GA30 Approved [29]
Leflunomide DMR8ONJ Arthritis FA20 Approved [30]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial (CYP27B1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [24]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [31]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [32]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [33]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [34]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [35]
Melphalan DMOLNHF Hematologic disease 3C0Z Approved [36]
Arsenic DMTL2Y1 N. A. N. A. Approved [37]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [38]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [39]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Integrin-binding sialoprotein (IBSP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [40]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [10]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [41]
Magnesium DMU4ORS Ischemic stroke 8B11.5Z Approved [42]
Vitamin C DMXJ7O8 Adenocarcinoma 2D40 Approved [43]
Camptothecin DM6CHNJ Solid tumour/cancer 2A00-2F9Z Phase 3 [44]
GSK2816126 DMJDVW4 Solid tumour/cancer 2A00-2F9Z Phase 1 [45]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [46]
EUGENOL DM7US1H Discovery agent N.A. Patented [47]
alpha-ketoglutaric acid DM5LFYN Discovery agent N.A. Investigative [48]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cyclin-dependent kinase inhibitor 1 (CDKN1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [49]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [50]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [51]
Gefitinib DM15F0X Colon adenocarcinoma Approved [52]
Talazoparib DM1KS78 Breast cancer 2C60-2C65 Approved [53]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [54]
Etretinate DM2CZFA Keratosis ED56 Approved [55]
Prednisone DM2HG4X Acute asthma CA23 Approved [56]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [57]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [58]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Vitamin D3 receptor (VDR) TTK59TV VDR_HUMAN Antagonist [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Vitamin D(3) 24-hydroxylase (CYP24A1) DEFI12S CP24A_HUMAN Substrate [7]
Calcidiol 1-monooxygenase (CYP27B1) DE3FYEM CP27B_HUMAN Substrate [8]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (CYP24A1) OTG2T749 CP24A_HUMAN Gene/Protein Processing [9]
25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial (CYP27B1) OTTK98BH CP27B_HUMAN Biotransformations [10]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Gene/Protein Processing [10]
Integrin-binding sialoprotein (IBSP) OT29944Y SIAL_HUMAN Gene/Protein Processing [10]

References

1 Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant. 2007 May;7(5):1193-200.
2 Patterns of renal osteodystrophy 1?year after kidney transplantation. Nephrol Dial Transplant. 2021 Nov 9;36(11):2130-2139.
3 Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens. Osteoporos Int. 2017 Nov;28(11):3239-3249.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6921).
5 A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
6 Vitamin D in health and disease. Clin J Am Soc Nephrol. 2008 Sep;3(5):1535-41.
7 Asthma families show transmission disequilibrium of gene variants in the vitamin D metabolism and signalling pathway. Respir Res. 2006 Apr 6;7:60.
8 Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta. 2011 Jan;1814(1):186-99.
9 Retinoic acid via RARalpha inhibits the expression of 24-hydroxylase in human prostate stromal cells. Biochem Biophys Res Commun. 2005 Dec 30;338(4):1973-81. doi: 10.1016/j.bbrc.2005.10.178. Epub 2005 Nov 7.
10 Effects of 25-hydroxyvitamin D(3) on proliferation and osteoblast differentiation of human marrow stromal cells require CYP27B1/1alpha-hydroxylase. J Bone Miner Res. 2011 May;26(5):1145-53.
11 Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist. Blood. 2000 Nov 1;96(9):3188-94.
12 Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
13 Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets. 2008 Apr;9(4):345-59.
14 Synthesis and biological evaluations of A-ring isomers of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3. Bioorg Med Chem. 2000 Aug;8(8):2157-66.
15 In vivo metabolism of the vitamin D analog, dihydrotachysterol. Evidence for formation of 1 alpha,25- and 1 beta,25-dihydroxy-dihydrotachysterol metabolites and studies of their biological activity. J Biol Chem. 1993 Jan 5;268(1):282-92.
16 [Vitamin D2 or vitamin D3]. Rev Med Interne. 2008 Oct;29(10):815-20.
17 New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor... Contrib Nephrol. 2009;163:219-226.
18 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
19 Evidence for tissue- and cell-type selective activation of the vitamin D receptor by Ro-26-9228, a noncalcemic analog of vitamin D3. J Cell Biochem. 2003 Feb 1;88(2):267-73.
20 The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014 May;14(5):342-57.
21 DNA microarray analysis of vitamin D-induced gene expression in a human colon carcinoma cell line. Physiol Genomics. 2004 Apr 13;17(2):122-9. doi: 10.1152/physiolgenomics.00002.2003.
22 Actions of Vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology. 1995 Jan;136(1):20-6.
23 Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
24 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
25 Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
26 Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest. 2005 Jan;115(1):177-86.
27 19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia. Cancer Res. 2005 Mar 15;65(6):2488-97.
28 Similarities and differences between two modes of antagonism of the thyroid hormone receptor. ACS Chem Biol. 2011 Oct 21;6(10):1096-106.
29 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
30 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
31 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
32 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
33 Down-regulation by nuclear factor kappaB of human 25-hydroxyvitamin D3 1alpha-hydroxylase promoter. Mol Endocrinol. 2004 Oct;18(10):2440-50. doi: 10.1210/me.2002-0441. Epub 2004 Jul 8.
34 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
35 Differential regulation of vitamin D receptor (VDR) by the p53 Family: p73-dependent induction of VDR upon DNA damage. J Biol Chem. 2007 Oct 12;282(41):29847-54.
36 Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
37 Association of Arsenic Exposure with Whole Blood DNA Methylation: An Epigenome-Wide Study of Bangladeshi Adults. Environ Health Perspect. 2019 May;127(5):57011. doi: 10.1289/EHP3849. Epub 2019 May 28.
38 Increased mitochondrial ROS formation by acetaminophen in human hepatic cells is associated with gene expression changes suggesting disruption of the mitochondrial electron transport chain. Toxicol Lett. 2015 Apr 16;234(2):139-50.
39 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
40 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
41 Zoledronic acid up-regulates bone sialoprotein expression in osteoblastic cells through Rho GTPase inhibition. Biochem J. 2004 Dec 15;384(Pt 3):591-8. doi: 10.1042/BJ20040380.
42 Effect of surface chemical modification of bioceramic on phenotype of human bone-derived cells. J Biomed Mater Res. 1999 Mar 15;44(4):389-96. doi: 10.1002/(sici)1097-4636(19990315)44:4<389::aid-jbm4>3.0.co;2-o.
43 Potential osteoinductive effects of calcitriol on the m-RNA of mesenchymal stem cells derived from human alveolar periosteum. Biomed Res Int. 2016;2016:3529561.
44 ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res. 2014 Dec 1;74(23):6968-79.
45 Epigenetic control of skeletal development by the histone methyltransferase Ezh2. J Biol Chem. 2015 Nov 13;290(46):27604-17.
46 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
47 Cytotoxic effect of eugenol on the expression of molecular markers related to the osteogenic differentiation of human dental pulp cells. Odontology. 2011 Jul;99(2):188-92. doi: 10.1007/s10266-011-0009-2. Epub 2011 Jun 26.
48 Alpha ketoglutarate exerts a pro-osteogenic effect in osteoblast cell lines through activation of JNK and mTOR/S6K1/S6 signaling pathways. Toxicol Appl Pharmacol. 2019 Jul 1;374:53-64.
49 Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis. 2005 Mar;20(2):139-46. doi: 10.1093/mutage/gei019. Epub 2005 Mar 22.
50 Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
51 Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
52 Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
53 BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
54 Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
55 Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
56 Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biol Ther. 2004 May;3(5):470-6. doi: 10.4161/cbt.3.5.838. Epub 2004 May 9.
57 Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
58 Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.